PMID- 23231807
OWN - NLM
STAT- MEDLINE
DCOM- 20131104
LR  - 20171116
IS  - 1873-7064 (Electronic)
IS  - 0028-3908 (Linking)
VI  - 67
DP  - 2013 Apr
TI  - Quercetin protects against the Abeta(25-35)-induced amnesic injury: involvement of 
      inactivation of rage-mediated pathway and conservation of the NVU.
PG  - 419-31
LID - S0028-3908(12)00565-5 [pii]
LID - 10.1016/j.neuropharm.2012.11.018 [doi]
AB  - Quercetin has demonstrated protective effects against Abeta-induced toxicity on both 
      neurons and endothelial cells. However, whether or not quercetin has an effect on 
      the neurovascular coupling is unclear. In the present study, we aim to 
      investigate the anti-amnesic effects of quercetin and to explore the underlying 
      mechanisms. Abeta(25-35) (10 nmol) was administrated to mice i.c.v. Quercetin was 
      administrated orally for 8 days after injection. Learning and memory behaviors 
      were evaluated by measuring spontaneous alternation in Morris Water Maze test and 
      the step-through positive avoidance test. The regional cerebral blood flow was 
      monitored before the Abeta(25-35) injection and on seven consecutive days after 
      injection. Mice were sacrificed and cerebral cortices were isolated on the last 
      day. The effects of quercetin on the neurovascular unit (NVU) integrity, 
      microvascular function and cholinergic neuronal changes, and the modification of 
      signaling pathways were tested. Our results demonstrate that quercetin treatment 
      for Abeta(25-35)-induced amnesic mice improved the learning and memory capabilities 
      and conferred robust neurovascular coupling protection, involving maintenance of 
      the NVU integrity, reduction of neurovascular oxidation, modulation of 
      microvascular function, improvement of cholinergic system, and regulation of 
      neurovascular RAGE signaling pathway and ERK/CREB/BDNF pathway. In conclusion, in 
      Abeta(25-35)-induced amnesic mice, optimal doses of quercetin administration were 
      beneficial. Quercetin protected the NVU likely through reduction of oxidative 
      damage, inactivation of RAGE-mediated pathway and preservation of cholinergic 
      neurons, offering an alternative medication for Alzheimer's disease.
CI  - Copyright (c) 2012 Elsevier Ltd. All rights reserved.
FAU - Liu, Rui
AU  - Liu R
AD  - Beijing Key Laboratory of Drug Target and Screening Research, Institute of 
      Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical 
      College, 1 Xiannongtan Street, Beijing 100050, PR China.
FAU - Zhang, Tian-tai
AU  - Zhang TT
FAU - Zhou, Dan
AU  - Zhou D
FAU - Bai, Xiao-yu
AU  - Bai XY
FAU - Zhou, Wei-ling
AU  - Zhou WL
FAU - Huang, Chao
AU  - Huang C
FAU - Song, Jun-ke
AU  - Song JK
FAU - Meng, Fang-rui
AU  - Meng FR
FAU - Wu, Cai-xia
AU  - Wu CX
FAU - Li, Lin
AU  - Li L
FAU - Du, Guan-hua
AU  - Du GH
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20121208
PL  - England
TA  - Neuropharmacology
JT  - Neuropharmacology
JID - 0236217
RN  - 0 (Amyloid beta-Peptides)
RN  - 0 (Neuroprotective Agents)
RN  - 0 (Peptide Fragments)
RN  - 0 (Plant Extracts)
RN  - 0 (Receptor for Advanced Glycation End Products)
RN  - 0 (Receptors, Immunologic)
RN  - 0 (amyloid beta-protein (25-35))
RN  - 9IKM0I5T1E (Quercetin)
SB  - IM
MH  - Amnesia/chemically induced/*metabolism/*prevention & control
MH  - Amyloid beta-Peptides/administration & dosage/*toxicity
MH  - Animals
MH  - Cerebral Cortex/drug effects/metabolism/pathology
MH  - Injections, Intraventricular
MH  - Male
MH  - Mice
MH  - Neural Pathways/drug effects/physiology
MH  - Neuroprotective Agents/*administration & dosage
MH  - Peptide Fragments/administration & dosage/*toxicity
MH  - Plant Extracts/administration & dosage
MH  - Quercetin/*administration & dosage
MH  - Receptor for Advanced Glycation End Products
MH  - Receptors, Immunologic/antagonists & inhibitors/*metabolism
EDAT- 2012/12/13 06:00
MHDA- 2013/11/05 06:00
CRDT- 2012/12/13 06:00
PHST- 2012/03/21 00:00 [received]
PHST- 2012/11/15 00:00 [revised]
PHST- 2012/11/20 00:00 [accepted]
PHST- 2012/12/13 06:00 [entrez]
PHST- 2012/12/13 06:00 [pubmed]
PHST- 2013/11/05 06:00 [medline]
AID - S0028-3908(12)00565-5 [pii]
AID - 10.1016/j.neuropharm.2012.11.018 [doi]
PST - ppublish
SO  - Neuropharmacology. 2013 Apr;67:419-31. doi: 10.1016/j.neuropharm.2012.11.018. 
      Epub 2012 Dec 8.